Health Care & Life Sciences » Pharmaceuticals | Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. Cl A | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
689.00
1,450.00
6,227.00
47,671.00
80,546
Depreciation, Depletion & Amortization
2,512.00
1,819.00
682.00
437.00
431
Other Funds
-
864.00
4.00
-
12,445
Funds from Operations
23,243.00
20,248.00
3,178.00
40,566.00
67,670
Changes in Working Capital
111,873.00
64,868.00
16,081.00
42,690.00
16,113
Net Operating Cash Flow
88,630.00
44,620.00
19,259.00
83,256.00
83,783
Capital Expenditures
183.00
272.00
340.00
344.00
Sale of Fixed Assets & Businesses
43.00
12.00
1.00
1.00
Net Investing Cash Flow
140.00
260.00
339.00
343.00
Issuance/Reduction of Debt, Net
-
45.00
220.00
19,481.00
Net Financing Cash Flow
1.00
870.00
62,322.00
128,647.00
Net Change in Cash
88,769.00
45,750.00
42,724.00
45,048.00
Free Cash Flow
88,813.00
44,892.00
19,599.00
83,600.00
Deferred Taxes & Investment Tax Credit
18,316.00
17,802.00
-
-
-
Change in Capital Stock
1.00
39.00
62,098.00
109,166.00

About Reata Pharmaceuticals

View Profile
Address
2801 Gateway Drive
Irving Texas 75063
United States
Employees -
Website http://www.reatapharma.com
Updated 07/08/2019
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.